Reduced intensity alemtuzumab-containing allogeneic stem cell transplantation for relapsed/refractory low grade lymphoma: reflections on a single center experience

Leuk Lymphoma. 2019 Dec;60(12):3075-3077. doi: 10.1080/10428194.2019.1607323. Epub 2019 May 13.

Affiliation

¹ Department of Haematology, University Hospitals Birmingham, Birmingham, UK.

PMID: 31079514
DOI: 10.1080/10428194.2019.1607323

No abstract available

Publication types

Letter

MeSH terms

Alemtuzumab / administration & dosage*
Antineoplastic Agents, Immunological / administration & dosage*
Cause of Death
Drug Resistance, Neoplasm
Female
Hematopoietic Stem Cell Transplantation* / adverse effects
Hematopoietic Stem Cell Transplantation* / methods
Humans
Lymphoma / mortality
Lymphoma / pathology*
Lymphoma / therapy*
Male
Prognosis
Recurrence
Retreatment
Transplantation Conditioning* / adverse effects
Transplantation Conditioning* / methods
Transplantation, Homologous
Treatment Outcome

Substances

Antineoplastic Agents, Immunological
Alemtuzumab